Clinical Trial

Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG)

Study acronym: BLINA-MG
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluating the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis and exploring the immunological mechanisms of Blinatumomab therapy in refractory myasthenia gravis. The main questions it aims to answer are: Will Blinatumomab improve the symptoms of participants? What medical problems do participants have when using Blinatumomab? Participants will: Continuous intravenous infusion of Blinatumomab for 5 days, pause for one week, and continue continuous intravenous infusion for 5 days Visit the clinic once every 1 month for checkups and tests Keep a diary of their symptoms
Trial Details
NCT Number NCT06684184
Lead Sponsor Zhongming Qiu
Conditions Myasthaenia Gravis
Enrollment 10 participants
Start Date 2024-11-30
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-12